Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.84 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.84 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915796 | 0.91 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| Hydrochloric Acid SCHEMBL2917512 | 0.91 | S1PR1 (0.99) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL3083031 | 0.89 | S1PR1 (0.86) | S1PR1S1PR3CYP2C9 | |
| Hydrochloric Acid SCHEMBL3080946 | 0.88 | S1PR1 (0.85) | S1PR1S1PR3CYP2C9 | |
| SCHEMBL2917146 | 0.81 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL2916357 | 0.81 | S1PR1 (0.80) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3082234 | 0.81 | S1PR1 (1.00) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL3091196 | 0.80 | S1PR1 (0.60) | S1PR1S1PR3S1PR5CYP2C9 | |
| Hydrochloric Acid SCHEMBL2914702 | 0.80 | S1PR1 (0.99) | S1PR1S1PR3S1PR5CYP2C9 | |
| SCHEMBL10455720 | 0.78 | S1PR1 (0.77) | S1PR1S1PR3S1PR5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | claimed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2220077-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080730-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273770-A1 | 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SSB, RORC, OXA1L | S1PR1 605/4885S1PR3 505/4885S1PR5 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.